{
    "2019-10-30": [
        [
            {
                "time": "",
                "original_text": "【国盛证券张金洋团队】恒瑞医药：两大品种申报上市，在研管线超预期推进",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "两大品种",
                        "申报上市",
                        "在研管线",
                        "超预期推进"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "414股获券商买入评级 天虹股份目标涨幅达72.04%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "天虹股份",
                        "目标涨幅",
                        "72.04%"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}